Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

Showing session: reset

Game Changers in Prevention of HIV and Sexually Transmitted Infections

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 12 of 12
INTRODUCTIONS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Phase I Safety, Tolerability and Pharmacokinetics of Tenofovir Alafenamide Implants in African Women   (ABSTRACT 123)
Tanuja N. Gengiah
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Final Results of ANRS 174 DOXYVAC: A Randomized Trial to Prevent STI in MSM on PrEP   (ABSTRACT 124)
Jean-Michel G. Molina
University of Paris-Est, Paris, France
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Sustained Reduction of Bacterial STIs During the DoxyPEP Study Open-Label Extension   (ABSTRACT 125)
Annie Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Doxycycline PEP: High Uptake and Significant Decline in STIs After Clinical Implementation   (ABSTRACT 126)
Hyman M. Scott
San Francisco Department of Public Health, San Francisco, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 1)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Doxy-PEP Associated With Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco   (ABSTRACT 127)
Madeline Sankaran
San Francisco Department of Public Health, San Francisco, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Site-Based HIV Testing Assay Performance for Cabotegravir and TDF-FTC PrEP Failure in HPTN 083   (ABSTRACT 128)
Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV   (ABSTRACT 129)
Gillian Gillespie
Merck & Co., Inc.,
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval   (ABSTRACT 130)
Kelong Han
GSK
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083   (ABSTRACT 131)
Meredith Clement
Louisiana State University, New Orleans, LA, USA
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
QUESTIONS AND ANSWERS (Part 2)
from CROI 2024 on March 4, 2024 10:00 AM-12:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 12 of 12